Actively Recruiting
Phase 1 Study of Safety and Dose Finding for Allogeneic Adipose-Derived Mesenchymal Stem Cells in Treating Recurrent Glioblastoma and Astrocytoma During Brain Surgery
Led by Mayo Clinic · Updated on 2026-04-02
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells AMSCs for patients with recurrent glioblastoma or astrocytoma undergoing brain surgery. Glioblastoma is the most common and aggressive brain tumor, and despite standard treatments like surgery, radiation, chemotherapy, and tumor treating fields, survival remains low with frequent recurrence. This phase I trial aims to explore whether AMSCs delivered directly into the surgical cavity during craniotomy can affect tumor growth and improve outcomes. Participants receive AMSCs injected into the tumor area during a craniotomy, along with placement of an Ommaya reservoir to collect cerebrospinal fluid CSF. Patients undergo magnetic resonance imaging MRI and provide blood, tissue, and CSF samples throughout the study. The study follows a dose-escalation design to determine the maximum tolerated dose of AMSCs. During the trial, participants are monitored closely with MRI scans and sample collections to assess safety, immune response, and tumor behavior. Follow-up visits occur every two months for one year to evaluate adverse effects, progression-free survival, and overall survival. The research also looks at changes in brain tissue over time and presence of AMSCs at recurrence, with safety monitored up to five years.
CONDITIONS
Brief Title
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Research Team
C
Clinical Trials Referral Office
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here